Helei Hou

529 total citations
12 papers, 377 citations indexed

About

Helei Hou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Helei Hou has authored 12 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Helei Hou's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Helei Hou is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Helei Hou collaborates with scholars based in China, Australia and United States. Helei Hou's co-authors include Dantong Sun, Xiaochun Zhang, Dong Liu, Chuantao Zhang, Xiaochun Zhang, Jingjuan Zhu, Deze Zhao, Hua Tian, Hefen Sun and Jinjun Li and has published in prestigious journals such as Frontiers in Immunology, Molecular Cancer Therapeutics and BMC Cancer.

In The Last Decade

Helei Hou

11 papers receiving 373 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Helei Hou China 8 216 172 125 102 34 12 377
Catherine J. Drummond United Kingdom 14 248 1.1× 159 0.9× 93 0.7× 66 0.6× 39 1.1× 24 452
Liz J. Hernández Borrero United States 2 260 1.2× 136 0.8× 68 0.5× 120 1.2× 29 0.9× 2 441
Vishal Das India 6 236 1.1× 186 1.1× 81 0.6× 150 1.5× 52 1.5× 7 485
Zhouwei Zhang United States 12 209 1.0× 110 0.6× 99 0.8× 145 1.4× 36 1.1× 19 359
Yi‐Fang Tsai Taiwan 13 219 1.0× 173 1.0× 94 0.8× 123 1.2× 41 1.2× 47 473
Lokman Varışlı Türkiye 11 261 1.2× 94 0.5× 88 0.7× 100 1.0× 17 0.5× 28 410
Ya-Ling Wei Taiwan 11 256 1.2× 216 1.3× 101 0.8× 101 1.0× 29 0.9× 19 448
Chengjuan Zhang China 15 239 1.1× 174 1.0× 123 1.0× 121 1.2× 42 1.2× 39 477
Mingzhu Huang China 13 211 1.0× 157 0.9× 99 0.8× 111 1.1× 27 0.8× 36 422
Carlo Vitagliano Italy 10 252 1.2× 182 1.1× 62 0.5× 84 0.8× 28 0.8× 15 387

Countries citing papers authored by Helei Hou

Since Specialization
Citations

This map shows the geographic impact of Helei Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helei Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helei Hou more than expected).

Fields of papers citing papers by Helei Hou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helei Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helei Hou. The network helps show where Helei Hou may publish in the future.

Co-authorship network of co-authors of Helei Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Helei Hou. A scholar is included among the top collaborators of Helei Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helei Hou. Helei Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Sun, Dantong, Helei Hou, Tongji Xie, et al.. (2025). A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma. Experimental Hematology and Oncology. 14(1). 3–3. 5 indexed citations
3.
Sun, Dantong, Zhen Yang, Yongzhi Lu, et al.. (2024). SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response. FEBS Open Bio. 14(12). 2086–2103. 5 indexed citations
4.
Hou, Helei, et al.. (2024). [Antitumor effects of redox-responsive nanoparticles containing platinum（Ⅳ）in ovarian cancer].. PubMed. 46(1). 76–85. 1 indexed citations
5.
Hou, Helei, Dantong Sun, Chuantao Zhang, Dong Liu, & Xiaochun Zhang. (2021). ALKrearrangements as mechanisms of acquired resistance to osimertinib inEGFRmutant non‐small cell lung cancer. Thoracic Cancer. 12(6). 962–969. 15 indexed citations
6.
Sun, Dantong, et al.. (2020). The role of CD28 in the prognosis of young lung adenocarcinoma patients. BMC Cancer. 20(1). 910–910. 9 indexed citations
7.
Zhao, Deze, Man Jiang, Xiaochun Zhang, & Helei Hou. (2020). The role of RICTOR amplification in targeted therapy and drug resistance. Molecular Medicine. 26(1). 20–20. 20 indexed citations
8.
Sun, Dantong, Yan Zhu, Jingjuan Zhu, et al.. (2020). Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC. Molecular Medicine. 26(1). 66–66. 17 indexed citations
9.
Hou, Helei, Kang Qin, Liang Yu, et al.. (2019). <p>Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC</p>. Cancer Management and Research. Volume 11. 5665–5675. 54 indexed citations
10.
Hou, Helei, Dantong Sun, & Xiaochun Zhang. (2019). The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell International. 19(1). 216–216. 162 indexed citations
11.
12.
Hou, Helei, Hefen Sun, Ping Lü, et al.. (2013). Tunicamycin Potentiates Cisplatin Anticancer Efficacy through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 12(12). 2874–2884. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine J. Drummond Breakdown of academic impact, for papers by Liz J. Hernández Borrero Breakdown of academic impact, for papers by Vishal Das Breakdown of academic impact, for papers by Zhouwei Zhang Breakdown of academic impact, for papers by Yi‐Fang Tsai Breakdown of academic impact, for papers by Lokman Varışlı Breakdown of academic impact, for papers by Ya-Ling Wei Breakdown of academic impact, for papers by Chengjuan Zhang Breakdown of academic impact, for papers by Mingzhu Huang Breakdown of academic impact, for papers by Carlo Vitagliano
Rankless by CCL
2026